| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Nanatinostat is a class I-selective HDAC inhibitor that primarily targets HDAC1, HDAC2, and HDAC3. By inhibiting these enzymes, it causes accumulation of highly acetylated histones, leading to chromatin remodeling and reactivation of silenced tumor suppressor genes. This results in cell cycle arrest, differentiation, and apoptosis in cancer cells. Nanatinostat's selectivity for class I HDACs over class II HDACs may contribute to its therapeutic index and safety profile.
|
|---|---|
| ln Vitro |
Nanatinostat potently inhibits HDAC1, HDAC2, and HDAC3 with IC50 values of 3 nM, 4 nM, and 7 nM, respectively, and has an overall IC50 of 8 nM. It demonstrates class I selectivity over class II HDACs. In cellular assays, Nanatinostat induces histone hyperacetylation, leading to cell cycle arrest and apoptosis in cancer cell lines, including EBV-associated gastric cancer cells. These in vitro activities establish its potency and selectivity as an HDAC inhibitor.
|
| ln Vivo |
Nanatinostat is orally bioavailable and has been evaluated in preclinical animal models of cancer, including EBV-associated gastric cancer. It induces tumor growth inhibition and regression in xenograft models, correlating with histone hyperacetylation and modulation of gene expression. Nanatinostat has entered clinical trials for cancer and inflammatory diseases. Its oral bioavailability and brain penetration properties support its development for systemic and CNS-related conditions.
|
| Enzyme Assay |
For non-cell HDAC inhibition assays, recombinant HDAC1, HDAC2, or HDAC3 is incubated with a fluorogenic acetylated peptide substrate in the presence of Nanatinostat at various concentrations. Enzyme activity is measured by detecting the release of fluorescent product. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
For cell-based assays, cancer cell lines are cultured in standard media and treated with Nanatinostat at various concentrations. Histone acetylation is assessed by Western blotting using acetylated histone antibodies. Cell viability is measured by MTT or sulforhodamine B assay. Apoptosis is assessed by flow cytometry using annexin V/PI staining or caspase-3 activity assays.
|
| Animal Protocol |
For in vivo antitumor studies, tumor xenografts are established in immunodeficient mice by subcutaneous implantation of cancer cells. Nanatinostat is administered orally at doses determined from pharmacokinetic studies. Tumor volume is measured regularly. Tumor tissues are collected for analysis of histone acetylation, gene expression, and apoptosis markers by immunohistochemistry and Western blotting.
|
| References |
|
| Molecular Formula |
C22H20F4N6O4
|
|---|---|
| Molecular Weight |
508.43
|
| Exact Mass |
394.1554
|
| CAS # |
1256448-48-2
|
| Related CAS # |
914937-68-1 (racemic);1256448-47-1;1256448-48-2 (TFA);2648504-17-8 (hydrate); 1256448-48-2 (TFA); 1235859-13-8 (deleted);
|
| PubChem CID |
131888677
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
36
|
| Complexity |
675
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1[C@@H]2[C@@H](C2NCC3=NC4=C(C=C3)C=C(C=C4)F)CN1C5=NC=C(C=N5)C(=O)NO.C(=O)(C(F)(F)F)O
|
| InChi Key |
WNMHEOGBNZYJGD-MPSOVPLESA-N
|
| InChi Code |
InChI=1S/C20H19FN6O2.C2HF3O2/c21-12-2-4-16-11(7-12)1-3-13(24-16)8-23-18-14-9-27(10-15(14)18)20-22-6-5-17(25-20)19(28)26-293-2(4,5)1(6)7/h1-7,14-15,18,23,29H,8-10H2,(H,26,28)(H,6,7)/t14-,15+,18+
|
| Chemical Name |
2-((1R,5S,6s)-6-(((6-fluoroquinolin-2-yl)methyl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)-N-hydroxypyrimidine-4-carboxamide trfluoroacetic acid
|
| Synonyms |
Nanatinostat TFATractinostat VRx-3996 TFA CHR 3996 VRx3996CHR-3996 CHR3996
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9668 mL | 9.8342 mL | 19.6684 mL | |
| 5 mM | 0.3934 mL | 1.9668 mL | 3.9337 mL | |
| 10 mM | 0.1967 mL | 0.9834 mL | 1.9668 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.